Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.00.

Several equities analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective for the company.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Verition Fund Management LLC acquired a new position in shares of Aquestive Therapeutics in the third quarter worth approximately $995,000. State Street Corp raised its holdings in Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Harvey Capital Management Inc. lifted its position in shares of Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after purchasing an additional 249,790 shares during the period. Wellington Management Group LLP bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at $922,000. Finally, Chartwell Investment Partners LLC bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at $535,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Up 2.2 %

Shares of Aquestive Therapeutics stock opened at $2.79 on Thursday. The firm has a market capitalization of $254.39 million, a PE ratio of -6.20 and a beta of 2.76. The firm’s 50 day moving average is $3.14 and its 200 day moving average is $4.14. Aquestive Therapeutics has a 1 year low of $2.24 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. As a group, research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.